Guidelines for mycobacterial infection prevention

List guidelines for mycobacterial infection prevention in patients who are to receive biologic agents?

  • • All patients who are to receive biologic agents should undergo MTB (latent and active) and NTM screening.
    • All patients should have risk factor assessment, physical examination, and a chest radiograph.
    • Tuberculin skin test only has a sensitivity and specificity of 70%. PPD >5 mm at 48 hours should be considered positive regardless of prior history of BCG vaccination.
    • Many patients with immune-mediated inflammatory diseases are on prednisone and other immunosuppressants, which can make PPD unreliable. Therefore, IGRA screening is also recommended. Notably, up to 10% of IGRA tests can be indeterminate in patients on immunosuppressants. Consequently, a dual testing strategy (perform one test and, if negative, perform the other) may be used, in which a positive result from either test would be considered positive.
    • Screening procedures decrease reactivation of MTB by 80%.
    • In the United States, NTM (especially MAC) is much more common than MTB. There are no skin tests or blood tests to detect NTM infection.
  • • Biologic therapy: Monoclonal antibodies (especially infliximab) against TNFα have the highest risk, and abatacept and rituximab have the lowest risk for MTB and NTM infection. Reactivation of MTB tends to occur within 6 months of starting anti-TNFα therapy and usually presents as extrapulmonary disease, especially lymphadenitis.
  • • Patients with latent MTB and normal chest radiograph should delay biologic initiation (especially anti-TNFα agents) until 1 month of latent TB therapy has been administered. Patients should receive a complete course for latent MTB (typically 9 months of isoniazid or 4 months of rifampin).
  • • Patients with active MTB should have a complete course of anti-tuberculous therapy before starting a biologic (especially anti-TNFα agent).
  • • Patients with prior history of treated NTM infection should be evaluated by a specialist before a biologic is used. Some NTM are difficult to cure, and anti-TNFα agents should be avoided. Rituximab or abatacept may be safer agents.
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top